Ventura Forecasts 39% Upside Potential in Healthcare Stock, a Long-Term Investment Opportunity

Park Medi World Ltd (PMWL) Initiated with 'Buy' Rating by Ventura Securities

Key Highlights

• Ventura Securities has initiated coverage on Park Medi World Ltd (PMWL) with a 'Buy' rating and a target price of ₹284, indicating an upside potential of 38.4% over the next 24 months.
• PMWL is expected to benefit from strong structural tailwinds, aggressive capacity expansion, and a capital-efficient operating model.
• The company operates a differentiated model in the affordable healthcare segment, with a focus on execution, scale, and cost efficiency.

Company Overview

Read also: Oshea Herbals Aims for Rs 650 Crore Revenue Amidst Expansion Efforts

Park Medi World Ltd (PMWL) is a hospital chain that has built a capital-efficient, asset-owned hospital network focused on affordable healthcare. The company operates with one of the lowest capex per bed in the industry at ₹34 lakh per bed, supported by its asset ownership structure and optimized hospital design.

Key Strengths

• Cluster-based "Pearl & Necklace" strategy, which builds dense hospital networks within a 30-40 km radius, improves doctor utilization, supports equipment sharing, and allows centralized procurement.
• Strong visibility on capacity expansion, with plans to add 1,850 beds over the next 24 months, taking total bed capacity to 5,460 beds by FY28E.
• Ability to acquire and revive distressed hospitals, which has emerged as a meaningful contributor to revenue and profitability.

Industry Backdrop

Read also: Suzlon to Expand Business Scope Beyond Wind Energy, Invests Rs 500 Crore in New Subsidiary This Fiscal Year

India's healthcare delivery market is estimated at ₹6.9-7.0 trillion in FY25 and is projected to reach ₹10.2-10.8 trillion by FY29, implying a 10-12% CAGR. North India, PMWL's core operating region, is among the fastest-growing healthcare markets.

Financial Projections

• Revenue expected to grow at a CAGR of 22.3% to ₹2,550 crore by FY28E, driven by capacity addition and low single-digit growth in ARPOB.
• EBITDA and PAT expected to grow at 22.4% and 28.4% CAGR, respectively, to ₹685 crore and ₹434 crore.
• EBITDA margins expected to remain broadly stable, while PAT margins may expand by 230 basis points to 17.0%.

Key Risks

• Slower-than-expected occupancy ramp-up in newly commissioned hospitals.
• RoE expected to dilute by 420 basis points to 15.0% due to the recent IPO and infusion of ₹770 crore in primary proceeds.